Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 256 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Phase | EXPERIMENTAL | Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256. |
| Dose Expansion Phase: Group 1 | EXPERIMENTAL | Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study. |
| Dose Expansion Phase: Group 2 | EXPERIMENTAL | Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study. |
| Name | Type | Description |
|---|---|---|
| AMG 256 | DRUG | AMG 256 administered as an intravenous (IV) infusion. |
Inclusion Criteria: * Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age ≥ 18 years at the time of signing informed consent. * Life expectancy of \> 3 months, in the opinion of the investigator. * Participant must have histologically or ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AMG 256 is an investigational therapy being studied for the treatment of advanced solid tumors. It is a small molecule developed by Amgen Inc. and has been evaluated in a Phase 1 clinical trial in adult patients with advanced solid tumors. It is not approved for any indication.
AMG 256 targets PD-1, a protein that functions as an immune checkpoint. By binding to PD-1, the drug is designed to interfere with PD-1 mediated signaling in the tumor microenvironment. This mechanism is intended to support antitumor immune activity in patients with advanced solid tumors.
AMG 256 is developed by Amgen Inc., which trades on the Nasdaq under the ticker AMGN. Amgen is the sponsor of the clinical program evaluating AMG 256 in advanced solid tumors.
AMG 256 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA for any indication. The Phase 1 study in advanced solid tumors has been completed.
AMG 256 has been evaluated in one clinical trial, NCT04362748, titled Study of AMG 256 in Adult Subjects With Advanced Solid Tumors. This completed Phase 1 trial enrolled 34 adult patients across the United States, Australia, Belgium, and Spain. It was a controlled study without randomization or double blinding.